These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 28293834)

  • 21. Combinations of cyclophilin inhibitor NIM811 with hepatitis C Virus NS3-4A Protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance.
    Mathy JE; Ma S; Compton T; Lin K
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3267-75. PubMed ID: 18591281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic Activity of Combined NS5A Inhibitors.
    O'Boyle DR; Nower PT; Gao M; Fridell R; Wang C; Hewawasam P; Lopez O; Tu Y; Meanwell NA; Belema M; Roberts SB; Cockett M; Sun JH
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1573-83. PubMed ID: 26711745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Establishment of a robust hepatitis C virus replicon cell line over-expressing P-glycoprotein that facilitates analysis of P-gp drug transporter effects on inhibitor antiviral activity.
    Hernandez D; Falk P; Yu F; Zhai G; Quan Y; Faria T; Cao K; Scola P; McPhee F
    Biochem Pharmacol; 2013 Jan; 85(1):21-8. PubMed ID: 23063413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ferrocene-based inhibitors of hepatitis C virus replication that target NS5A with low picomolar in vitro antiviral activity.
    Gadhachanda VR; Eastman KJ; Wang Q; Phadke AS; Patel D; Yang W; Marlor CW; Deshpande M; Huang M; Wiles JA
    Bioorg Med Chem Lett; 2018 Nov; 28(21):3463-3471. PubMed ID: 30290989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A cellular replicon-based phenotyping assay to determine susceptibility of hepatitis C virus clinical isolates to NS3/4A protease inhibitors.
    Vijgen L; Verbeeck J; Van Kerckhove B; Berke JM; Koletzki D; Fanning G; Lenz O
    Methods Mol Biol; 2013; 1030():105-17. PubMed ID: 23821263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A.
    Sun JH; O'Boyle DR; Fridell RA; Langley DR; Wang C; Roberts SB; Nower P; Johnson BM; Moulin F; Nophsker MJ; Wang YK; Liu M; Rigat K; Tu Y; Hewawasam P; Kadow J; Meanwell NA; Cockett M; Lemm JA; Kramer M; Belema M; Gao M
    Nature; 2015 Nov; 527(7577):245-8. PubMed ID: 26536115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of HCV replication by cyclophilin antagonists is linked to replication fitness and occurs by inhibition of membranous web formation.
    Madan V; Paul D; Lohmann V; Bartenschlager R
    Gastroenterology; 2014 May; 146(5):1361-72.e1-9. PubMed ID: 24486951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel nucleoside analogues targeting HCV replication through an NS5A-dependent inhibition mechanism.
    Lougiakis N; Frakolaki E; Karmou P; Pouli N; Marakos P; Madan V; Bartenschlager R; Vassilaki N
    Chem Biol Drug Des; 2017 Sep; 90(3):352-367. PubMed ID: 28245093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-nucleoside inhibitors of the hepatitis C virus NS5B RNA-dependant RNA polymerase: 2-aryl-3-heteroaryl-1,3-thiazolidin-4-one derivatives.
    Rawal RK; Katti SB; Kaushik-Basu N; Arora P; Pan Z
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6110-4. PubMed ID: 18947995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides.
    Chukkapalli V; Berger KL; Kelly SM; Thomas M; Deiters A; Randall G
    Virology; 2015 Feb; 476():168-179. PubMed ID: 25546252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of silyl proline containing HCV NS5A inhibitors with pan-genotype activity: SAR development.
    Nair AG; Zeng Q; Selyutin O; Rosenblum SB; Jiang Y; Yang DY; Keertikar K; Zhou G; Dwyer MP; Kim SH; Shankar B; Yu W; Tong L; Chen L; Mazzola R; Caldwell J; Tang H; Allard ML; Buckle RN; Gauuan PJ; Holst CL; Martin GS; Naicker KP; Vellekoop S; Agrawal S; Liu R; Kong R; Ingravallo P; Xia E; Zhai Y; Nomeir A; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Mar; 26(5):1475-9. PubMed ID: 26850003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis C virus resistance to protease inhibitors.
    Halfon P; Locarnini S
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of antiviral effects of novel NS5A inhibitors in hepatitis C virus cell culture system with full-genome infectious clones.
    Murayama A; Fujiwara K; Yamada N; Shiina M; Aly HH; Masaki T; Muramatsu M; Wakita T; Kato T
    Antiviral Res; 2018 Oct; 158():161-170. PubMed ID: 30118732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors.
    Chase R; Skelton A; Xia E; Curry S; Liu S; McMonagle P; Huang HC; Tong X
    Antiviral Res; 2009 Nov; 84(2):178-84. PubMed ID: 19747948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In silico identification, design and synthesis of novel piperazine-based antiviral agents targeting the hepatitis C virus helicase.
    Bassetto M; Leyssen P; Neyts J; Yerukhimovich MM; Frick DN; Courtney-Smith M; Brancale A
    Eur J Med Chem; 2017 Jan; 125():1115-1131. PubMed ID: 27810598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nucleoside analog inhibitors of hepatitis C virus replication.
    Carroll SS; Olsen DB
    Infect Disord Drug Targets; 2006 Mar; 6(1):17-29. PubMed ID: 16787301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors.
    McGivern DR; Masaki T; Williford S; Ingravallo P; Feng Z; Lahser F; Asante-Appiah E; Neddermann P; De Francesco R; Howe AY; Lemon SM
    Gastroenterology; 2014 Aug; 147(2):453-62.e7. PubMed ID: 24768676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action.
    Targett-Adams P; Graham EJ; Middleton J; Palmer A; Shaw SM; Lavender H; Brain P; Tran TD; Jones LH; Wakenhut F; Stammen B; Pryde D; Pickford C; Westby M
    J Virol; 2011 Jul; 85(13):6353-68. PubMed ID: 21507963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis of New Indanyl Nucleoside Analogues and their Biological Evaluation on Hepatitis C Virus (HCV) Replicon.
    Gómez ME; Gentile EA; Martini MF; Cuestas ML; Mathet VL; Moltrasio GY; Moglioni AG
    Molecules; 2019 Mar; 24(5):. PubMed ID: 30862130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HCV NS5A replication complex inhibitors.
    Gao M; O'Boyle DR; Roberts S
    Curr Opin Pharmacol; 2016 Oct; 30():151-157. PubMed ID: 27643675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.